Fredun Pharmaceuticals (539730) Q4 06/07 earnings summary

Executive summary

• FY 2006-07 sales turnover reached ₹444.54 lakh vs ₹394.75 lakh; net profit was ₹6.12 lakh vs ₹3.61 lakh.

• Growth outlook was described as better, supported by export orders on hand; no dividend was recommended to conserve resources.

Financial highlights

• Total income was ₹453.39 lakh vs ₹401.20 lakh; profit before tax was ₹8.36 lakh vs ₹1.67 lakh, after prior-year exceptional items of ₹1.78 lakh.

• Profit before interest and depreciation was ₹55.66 lakh vs ₹48.43 lakh; interest expense was ₹26.14 lakh vs ₹25.41 lakh, and depreciation was ₹21.16 lakh vs ₹19.57 lakh.

• Net profit after tax was ₹6.12 lakh vs ₹3.61 lakh; closing profit carried to reserves and surplus was ₹14.36 lakh.

• Sales comprised finished goods of ₹288.00 lakh and conversion charges of ₹156.54 lakh; other income was ₹8.85 lakh, including ₹7.74 lakh from DEPB licence sales.

Outlook and guidance

• Outlook for the year ahead was considered better, with good export orders on hand.

• A three-year wage agreement with Palghar factory workmen took effect 1 April 2007.